"Receptors, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Receptors on the plasma membrane of nonhepatic cells that specifically bind LDL. The receptors are localized in specialized regions called coated pits. Hypercholesteremia is caused by an allelic genetic defect of three types: 1, receptors do not bind to LDL; 2, there is reduced binding of LDL; and 3, there is normal binding but no internalization of LDL. In consequence, entry of cholesterol esters into the cell is impaired and the intracellular feedback by cholesterol on 3-hydroxy-3-methylglutaryl CoA reductase is lacking.
Descriptor ID |
D011973
|
MeSH Number(s) |
D12.776.543.750.710.450
|
Concept/Terms |
Receptors, LDL- Receptors, LDL
- LDL Receptors
- LDL Receptors, Lipoprotein
- Receptors, Lipoprotein LDL
- Lipoprotein LDL Receptors
- Low Density Lipoprotein Receptors
- Receptors, Lipoprotein, LDL
- Receptors, Low Density Lipoprotein
- LDL Receptor
- Receptor, LDL
- Low Density Lipoprotein Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptors, LDL".
Below are MeSH descriptors whose meaning is more specific than "Receptors, LDL".
This graph shows the total number of publications written about "Receptors, LDL" by people in this website by year, and whether "Receptors, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 1 | 0 | 1 |
1998 | 1 | 0 | 1 |
2007 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2013 | 0 | 1 | 1 |
2014 | 1 | 1 | 2 |
2015 | 1 | 1 | 2 |
2016 | 0 | 1 | 1 |
2017 | 0 | 2 | 2 |
2018 | 2 | 0 | 2 |
2021 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, LDL" by people in Profiles.
-
Deficient RPE mitochondrial energetics leads to subretinal fibrosis in age-related neovascular macular degeneration. Commun Biol. 2024 Sep 02; 7(1):1075.
-
Soluble very low-density lipoprotein receptor (sVLDLR) inhibits fibrosis in neovascular age-related macular degeneration. FASEB J. 2021 12; 35(12):e22058.
-
ADAM17 mediates ectodomain shedding of the soluble VLDL receptor fragment in the retinal epithelium. J Biol Chem. 2021 10; 297(4):101185.
-
Apoptotic Ablation of Platelets Reduces Atherosclerosis in Mice With Diabetes. Arterioscler Thromb Vasc Biol. 2021 03; 41(3):1167-1178.
-
Primary prevention of atherosclerosis by pretreatment of low-density lipoprotein receptor knockout mice with sesame oil and its aqueous components. Sci Rep. 2018 08 16; 8(1):12270.
-
SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice. Atherosclerosis. 2018 04; 271:166-176.
-
Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment. Am J Physiol Heart Circ Physiol. 2018 04 01; 314(4):H693-H703.
-
Therapeutic Effects of PPARa Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017 10 01; 58(12):5065-5075.
-
mTOR drives cerebral blood flow and memory deficits in LDLR-/- mice modeling atherosclerosis and vascular cognitive impairment. J Cereb Blood Flow Metab. 2018 01; 38(1):58-74.
-
Functional Differences of Very-Low-Density Lipoprotein Receptor Splice Variants in Regulating Wnt Signaling. Mol Cell Biol. 2016 10 15; 36(20):2645-54.